EPA Ethyl Ester Add-On Therapy for Residual Cardiovascular Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for cardiovascular diseases, such as Lovaza®, can increase LDL-C and/or non-HDL-C levels in some patients, and there is a need for improved methods to reduce cardiovascular risk in subjects on statin therapy.
Innovation Solution
Administering a pharmaceutical composition containing eicosapentaenoic acid ethyl ester (EPA) to subjects, particularly those on statin therapy, to reduce the risk of cardiovascular events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Lovaza is used to treat cardiovascular disease, then triglyceride levels are reduced, but LDL-C and/or non-HDL-C levels increase in some patients
Solution Approach 1:
The patent changes the chemical composition parameter by using high-purity eicosapentaenoic acid (EPA) ethyl ester (≥96% pure) instead of mixed omega-3 fatty acid formulations. This parameter change allows selective reduction of triglycerides without the harmful side effect of increasing LDL-C and non-HDL-C levels, resolving the technical contradiction between triglyceride reduction and LDL-C elevation.
2Quantity of substance
If statin therapy is used to reduce cardiovascular risk, then cholesterol levels are lowered, but cardiovascular events still occur in patients with persistent high triglycerides
Solution Approach 1:
The patent introduces high-purity EPA ethyl ester as an intermediary substance that works synergistically with statin therapy. This intermediary agent specifically targets residual triglyceride elevation that persists despite statin treatment, thereby enhancing the overall cardiovascular protection without interfering with statin's cholesterol-lowering mechanism.
Solution Approach 2:
The patent changes the therapeutic approach by adding a second agent (EPA ethyl ester) that acts on a different lipid parameter (triglycerides) rather than relying solely on statins for cholesterol control. This parameter diversification complements statin therapy and addresses the limitation of statins in preventing cardiovascular events in patients with persistent hypertriglyceridemia.
3Quantity of substance
If conventional omega-3 products are used, then triglyceride reduction is achieved, but cardiovascular event risk reduction is insufficient
Solution Approach 1:
The patent dramatically changes the purity parameter of the omega-3 fatty acid formulation, using ≥96% pure eicosapentaenoic acid ethyl ester instead of conventional mixed formulations. This parameter change concentrates the therapeutic activity, achieving both potent triglyceride reduction and significant cardiovascular event risk reduction (25-30% over five years) that conventional products cannot accomplish.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.